Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426350 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2LTA4HPTGS2TDP1SIGMAR1 | |
| SCHEMBL26157145 | 0.88 | SMN1; SMN2 (0.43) | SMN1; SMN2LTA4HSIGMAR1KDM4E | |
| SCHEMBL430014 | 0.87 | POLB (0.53) | SIGMAR1 | |
| SCHEMBL2143957 | 0.84 | LTA4H (0.51) | SMN1; SMN2LTA4HPTGS2TDP1SIGMAR1 | |
| SCHEMBL26157168 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2TDP1SIGMAR1KDM4E | |
| SCHEMBL15716661 | 0.81 | LTA4H (0.51) | LTA4HPTGS2SIGMAR1KDM4EL3MBTL1 | |
| SCHEMBL448151 | 0.81 | SRC (0.50) | SMN1; SMN2LTA4HPTGS2TDP1SIGMAR1 | |
| SCHEMBL18133481 | 0.81 | HTT (0.59) | SMN1; SMN2LTA4HPTGS2SIGMAR1KDM4E | |
| SCHEMBL427032 | 0.80 | SIGMAR1 (0.54) | SMN1; SMN2SIGMAR1KDM4E | |
| SCHEMBL448150 | 0.79 | LOXL2 (0.51) | SMN1; SMN2LTA4HPTGS2KDM4ECHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970323-B1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2017088738-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | 南京明德新药研发股份有限公司 | 2017-06-01 | — | — | WO | disclosed |
| US-9663533-B2 | Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2920183-B1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | BRD4, BET1, BRD3 | SMN1; SMN2 2089/4885LTA4H 1381/4885PTGS2 901/4885 |
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | SMN1; SMN2 3709/4885LTA4H 2031/4885PTGS2 1117/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | SMN1; SMN2 1829/4885LTA4H 417/4885PTGS2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.